RSV Vaccine May Be On Market In 2023, CDC’s ACIP Anticipates

 
• By Brenda Sandburg

Panel expects to review five respiratory syncytial virus vaccines and vote on one or two of them in June 2023 and others four months later. Sanofi presents results of three clinical trials of its monoclonal antibody nirsevimab, which is on track to be the second RSV prophylaxis for infants.

Respiratory syncytial virus
CDC advisory committee plans to review five RSV vaccines in the next year • Source: Shutterstock

More from US FDA Performance Tracker

More from Regulatory Trackers